Use of Whole‐Blood Transcriptomic Profiling to Highlight Several Pathophysiologic Pathways Associated With Response to Rituximab in Patients With Rheumatoid Arthritis: Data From a Randomized, Controlled, Open‐Label Trial
Authors:
Open Access
- 22 April 2014
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 66 (8) , 2015-2025
Abstract
Objective: To identify a molecular signature that could be predictive of the clinical response to rituximab (RTX) and elucidate the transcriptomic changes after RTX therapy in patients with rheumatoid arthritis (RA), with the use of whole‐blood transcriptomic profiling.Methods: A microarray assay of the whole human genome was performed using RNA from peripheral blood samples obtained before the first cycle of RTX from 68 patients with RA in the SMART study. The transcriptomic profile was also assessed 24 weeks after the first administration of RTX (among 24 nonresponders and 44 responders, according to the European League Against Rheumatism response criteria at week 24). Ingenuity Interactive Pathways Analysis was used to identify molecular pathways that were modified by RTX therapy according to the clinical response. Quantitative polymerase chain reaction was performed to confirm the microarray results.Results: In total, 198 genes showed significant baseline differential expression between patient groups according to their subsequent response to RTX (good or moderate responder versus nonresponder). This molecular signature could be reduced to 143 genes, which allowed for correctly classifying 89% of the patients by their EULAR response status at week 24, with 93% identification of responders and 100% identification of nonresponders. The signature for response featured up‐regulation of inflammatory genes centered on NF‐κB, including IL33 and STAT5A, and down‐regulation of the interferon pathway. As expected, at week 24 post–RTX therapy, genes involved in the development and functions of B cells were the genes most strongly down‐regulated, without any difference between the 2 groups.Conclusion: Whole‐blood transcriptomic analyses may accurately identify patients with RA who will not respond to RTX therapy. These findings could open new perspectives on the clinical management of RA.Keywords
Funding Information
- Roche
This publication has 30 references indexed in Scilit:
- CCL19, a B Cell Chemokine, Is Related to the Decrease of Blood Memory B Cells and Predicts the Clinical Response to Rituximab in Patients With Rheumatoid ArthritisArthritis & Rheumatism, 2013
- The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patientsArthritis Research & Therapy, 2012
- Importance of Correlation between Gene Expression Levels: Application to the Type I Interferon Signature in Rheumatoid ArthritisPLOS ONE, 2011
- Identification of tripartite motif-containing 22 (TRIM22) as a novel NF-κB activatorBiochemical and Biophysical Research Communications, 2011
- Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patientsArthritis & Rheumatism, 2010
- Identification of Candidate Genes for Rituximab Response in Rheumatoid Arthritis Patients by Microarray Expression Profiling in Blood CellsPharmacogenomics, 2009
- Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rateAnnals of the Rheumatic Diseases, 2009
- Consensus statement on the use of rituximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988